Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

This study has been completed.
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT01042119
First received: January 4, 2010
Last updated: June 23, 2010
Last verified: June 2010
  Purpose

The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.

The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.


Condition
Overactive Bladder Syndrome

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • duration of effect of Botox [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: January 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Botox
patients who received intravesical injections of botulinum neurotoxin type A

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients who received at our clinic treatment with intravesical injection of Botox for idiopathic overactive bladder syndrome

Criteria

Inclusion Criteria:

  • intravesical treatment with Botox at our clinic
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01042119

Locations
Switzerland
University Hospital of Zurich, Clinic for Gynaecology
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: David A Scheiner, MD University Hospital of Zurich, Clinic for Gynaecology
  More Information

No publications provided

Responsible Party: Scheiner, David, Dr. med., University Hospital of Zurich, Clinic for Gynaecology
ClinicalTrials.gov Identifier: NCT01042119     History of Changes
Other Study ID Numbers: FHKUSZ15-2009
Study First Received: January 4, 2010
Last Updated: June 23, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Zurich:
botulinum neurotoxin type A
BoNT/A
Botox
overactive bladder syndrome

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Botulinum Toxins, Type A
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014